Description
Interleukin (IL)-36 signaling has been shown to be increased in ulcerative colitis (UC). Spesolimab, a novel humanized monoclonal antibody, targets the IL-36 pathway. We report safety, immunogenicity, and efficacy data of intravenous (IV) spesolimab in ...
Date made available | 2022 |
---|---|
Publisher | Taylor & Francis |